21:00 , Aug 17, 2017 |  BC Innovations  |  Translation in Brief

Stopping the invasion

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it...
17:44 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could help treat glioblastoma multiforme (GBM). In mouse brain slices co-cultured with a patient-derived GBM cell line, vector-mediated constitutively active...
23:53 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Huntington's disease (HD) Patient sample and mouse studies suggest inhibiting CSNK2A2 could help treat HD. Levels of CSNK2A2 were higher in striatal tissue samples from HD patients and striatal and gastrocnemius muscle tissue samples...
07:00 , Mar 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Casein kinase 2 (CSNK2A1; CK2) Studies in cell culture suggest that inhibiting CK2 could be useful for...
07:00 , Oct 16, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) Phosphatase and tensin homolog (PTEN; MMAC1; TEP1); casein kinase 2 (CK2) In vitro studies suggest that...